Nasdaq:US$14.68 (+0.25) | HKEX:HK$23.26 (+0.38) | AIM:£2.20 (+0.01)
搜索
新闻档案

通过选择所需的新闻类型，可以获得最新的公告或演示文稿。

请使用 「新闻主题」进一步挑选公告类别。
 

所有公告的全文可以PDF文件的形式下载。为方便起见，某些公告的部分或全部文字内容以网页的方式呈现。如存有任何不一致之处，请以PDF版本为准。

新闻类型
公告及新闻稿
演示文稿
新闻主题
其他业务
监管通知
肿瘤学 / 免疫学
集团
1234567891011
12
1314151617181920
找到相关结果： 954
公告及新闻稿, 监管通知 | 2018-03-19

Director's Share Dealing
London: Monday, March 19, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notification that Dr Dan Eldar, Non-executive Director, purchased a total of 2,768 American Depositary Shares of the Company (“ADSs”,
阅读更多
公告及新闻稿, 集团 | 2018-03-12

Publication of Form 20-F for the Year Ended December 31, 2017
公告及新闻稿, 集团 | 2018-03-12

Chi-Med Reports Final Results for the Year Ended December 31, 2017 and Updates Shareholders on Key Clinical Programs
Hutchison China MediTech Limited (“Chi-Med”) Reports Final Results for the Year Ended December 31, 2017 and Updates Shareholders on Key Clinical Programs Group: Year of major progress; results in line with guidance Group revenue up 12% to $
阅读更多
演示文稿, 科学出版物 | 2018-03-12

Journal of Clinical Oncology: Phase II Trial of Fruquintinib in Patients with Advanced Nonsquamous NSCLC
 Shun Lu, Jianhua Chang, Xiaoqing Liu, Jianhua Shi, You Lu, Wei Li, Jin-ji Yang, Jianying Zhou, Jie Wang, Tongtong An, Lei Yang, Zhe Liu, Xiangdong Zhou, Mo Chen, Ye Hua and Weiguo Su Abstract Purpose Patients with advanced non‒small-cell lung
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2018-03-06

和黄医药在中国启动依吡替尼以胶质母细胞瘤为适应症的Ib/II期概念验证临床试验
2018年3月6日: 和黄医药今日宣布在中国启动依吡替尼Ib/II期概念验证临床试验，目标受试者为表皮生长因子受体（EGFR）基因扩增的胶质母细胞瘤患者。胶质母细胞瘤是脑肿瘤的一种主要类型
阅读更多
下载新闻稿 (PDF)
演示文稿, 科学出版物 | 2018-02-24

ACOS 2018: Adverse Events of Special Interest Profiles and Time Courses of Fruquintinib in the FRESCO Trial
Venue: The 13th International Conference of the Asian Clinical Oncology Society in Chiang Mai, Thailand Abstract #: ABS093 Authors: Jin Li, Shukui Qin, Yuxian Bai, Yanhong Deng, Lei Yang, Zhendong Chen, Haijun Zhong, Rui-hua Xu, Hongming Pan,
阅读更多
演示文稿, 科学出版物 | 2018-02-20

ICTO2018: Phase Ib of Savolitinib and Durvalumab in Renal Cell Carcinoma (CALYPSO)
A Phase Ib Study of Durvalumab (MEDI4736) in Combination with Savolitinib in Patients with Metastatic Renal Cell Carcinoma S Vari1, B Szabados1, A GomezdeLiano1, K Mousa2, L Rammazzo2, A Prendergast2, T Powles1 1 Barts Health NHS Trust, Barts Can
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2018-02-13

和黄医药完成呋喹替尼以非小细胞肺癌为适应症的III期临床试验的患者入组工作，共招募527名患者
2018年2月13日：和黄医药今日宣布呋喹替尼（HMPL-013）以非小细胞肺癌为适应症的III期临床试验“FALUCA”顺利完成患者入组工作。呋喹替尼是一种高选择性强效口服血管内皮生长因子受体（VEGF
阅读更多
下载新闻稿 (PDF)
公告及新闻稿, 监管通知 | 2018-02-05

Chi-Med to Announce 2017 Final Results
London: Monday, February 5, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its final results for the year ended December 31, 2017 on Monday, March 12, 2018 at 7:00 am Greenwich Mean Time (GMT). An analy
阅读更多
公告及新闻稿, 监管通知 | 2017-12-29

Total Voting Rights
London: Friday, December 29, 2017: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at December 29, 2017, the issued share capital of Chi-Med consisted of 66,447,037 ordin
阅读更多
公告及新闻稿, 监管通知 | 2017-12-29

Blocklisting Six Monthly Return
London: Friday, December 29, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited 2. Name of scheme: H
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-12-15

和黄医药在美国启动呋喹替尼临床试验
2017年12月15日：和黄医药今日宣布在美国启动呋喹替尼I期桥接临床试验。呋喹替尼是一种高选择性强效口服血管内皮生长因子受体（VEGFR）1,2及3的抑制剂。呋喹替尼在中国以结直肠癌、肺癌
阅读更多
下载新闻稿 (PDF)
公告及新闻稿, 监管通知 | 2017-11-01

TR-1: Notification of major interest in shares
公告及新闻稿, 监管通知 | 2017-11-01

TR-1: Notification of major interest in shares
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-10-31

和黄医药启动呋喹替尼以二线胃癌为适应症的III期临床研究FRUTIGA
2017年10月31日：和黄医药今日宣布在中国启动呋喹替尼联合紫杉醇（泰素®）以晚期胃癌或胃食管结合部（GEJ）腺癌为适应症的关键性III期临床研究，这项研究被命名为FRUTIGA 。呋喹替尼是一
阅读更多
下载新闻稿 (PDF)
公告及新闻稿, 集团 | 2017-10-30

Chi-Med Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising Approximately US$301.3 Million on the Nasdaq Global Select Market
London: Monday, October 30, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announced today the closing of its underwritten public offering of American Depositary Shares ("ADSs") on the Nasdaq Global Select Market, previously
阅读更多
公告及新闻稿, 集团 | 2017-10-27

Chi-Med Announces the Full Exercise of Underwriters' Over-allotment Option
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION London: Friday, October 27, 2017: Hutchison China MediTech L
阅读更多
公告及新闻稿, 集团 | 2017-10-26

Chi-Med Announces Pricing of U.S. Public Offering of ADSs Raising US$262 Million on Nasdaq Global Select Market (RNS)
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION London: Wednesday, October 25, 2017: Hutchison China MediTec
阅读更多
新闻稿, 集团 | 2017-10-26

Chi-Med Announces Pricing of U.S. Public Offering of ADSs Raising US$262 Million on Nasdaq Global Select Market
London: Wednesday, October 25, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announced today the pricing of the underwritten public offering previously announced by Chi-Med on October 24, 2017. Chi-Med will issue and sell 9
阅读更多
公告及新闻稿, 集团 | 2017-10-25

Chi-Med Announces Proposed Offering of ADSs (RNS)
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION London: Tuesday, October 24, 2017: Hutchison China MediTech
阅读更多
新闻稿, 集团 | 2017-10-24

Chi-Med Announces Proposed Offering of ADSs
London: Tuesday, October 24, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announced today that it intends to offer, subject to market and other conditions, US$262.0 million of American Depositary Shares (“ADSs”), each
阅读更多
公告及新闻稿, 监管通知 | 2017-10-19

TR-1: Notification of major interest in shares
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-10-17

和黄医药联合阿斯利康开发的沃利替尼二线治疗MET扩增的EGFR突变肺癌患者展现出良好的临床抗肿瘤活性
–沃利替尼联合泰瑞莎®或易瑞沙®的临床研究数据于世界肺癌大会公布–   –新公布的数据有助于理解MET扩增的EGFR突变NSCLC的疾病进展过程和探索潜在的新一代治疗策略 –   2017
阅读更多
下载新闻稿 (PDF)
演示文稿, 科学出版物 | 2017-10-17

WCLC 2017: Phase Ib/II savolitinib plus Iressa® in MET-driven NSCLC
OA 09.06 – A Phase Ib Trial of Savolitinib plus Gefitinib for Chinese Patients with EGFR-Mutant MET-Amplified Advanced NSCLC Jin-Ji Yang, Jian Fang, Y. Shu, J. Chang, G. Chen, J. He, W. Li, X. Liu, N. Yang, Caicun Zhou, J. Huang, L. Yang, A.A. Han
阅读更多
演示文稿, 科学出版物 | 2017-10-17

WCLC 2017: Phase Ib/II savolitinib plus Tagrisso® in MET-driven NSCLC
OA 09.03 – TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI Myung-Ju Ahn, Ji-Youn Han, Lecia V Sequist, Byoung Chul Cho, J.S. Lee, Sang-We Kim, W. Su, C. T
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-10-16

和黄医药公布呋喹替尼联合疗法用于肺癌一线治疗的II期临床研究初步结果
– 呋喹替尼联合易瑞沙®（吉非替尼）展现出良好的疗效和安全性 –   –进一步证实呋喹替尼因其高选择性和出众的安全性而具有与其他癌症疗法相联合的巨大潜力–   2017年10月1
阅读更多
下载新闻稿 (PDF)
演示文稿, 科学出版物 | 2017-10-15

WCLC 2017: Phase II fruquintinib combination with Iressa in NSCLC
JCSE 01.12 – A Phase II study of fruquintinib in combination with gefitinib in stage IIIb/IV NSCLC patients harboring EGFR activating mutations (NCT02976116) Shun Lu, Jianying Zhou, Xiaomin Niu, Mo Chen, Hongyan Yin, Ye Hua, Weiguo Su Venue: IA
阅读更多
公告及新闻稿, 新闻稿, 集团 | 2017-10-12

和黄医药董事会董事任命
2017年10月12日：和黄中国医药科技有限公司（简称“和黄医药”或“Chi-Med”）（纳斯达克/伦敦证交所：HCM）今日宣布任命莫树锦（Tony Mok）教授担任公司独立非执行董事，同时担任科学委员
阅读更多
下载新闻稿 (PDF)
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-09-29

Chi-Med Highlights Oral Presentations at CSCO Annual Meeting
Press Release   – Three oral presentations given at CSCO for fruquintinib, savolitinib and theliatinib – – Plenary keynote presentation for FRESCO Phase III trial details analysis showing consistent survival benefit in all key subgroups
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-09-29

Chi-Med to Present Savolitinib and Fruquintinib Clinical Data at WCLC 2017 Annual Meeting
Press Release – Data to show potential of savolitinib to treat EGFR-TKI resistance in both Iressa® and Tagrisso® refractory patients with MET amplification – – Results to further validate Chi-Med’s scientific strategy of designing highly
阅读更多
公告及新闻稿, 监管通知 | 2017-09-29

Total Voting Rights
London: Friday, September 29, 2017: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at September 29, 2017, the issued share capital of Chi-Med consisted of 60,750,132 ord
阅读更多
演示文稿, 科学出版物 | 2017-09-28

CSCO 2017: Savolitinib Phase Ib in c-MET Gastric Cancer
Phase Ib Trial of the Safety and Antitumor Activity of Savolitinib in Advanced Gastric Cancer Patients with Aberrant c-MET Jifeng Feng, Baorui Liu, Tianshu Liu, Nong Xu, Jianming Xu, Yunpeng Liu, Yuxian Bai, Jin Li, Wei Li, Chunmei Bai, Tao Zhang,
阅读更多
演示文稿, 科学出版物 | 2017-09-28

CSCO 2017: Theliatinib Phase I Results
Novel EGFR TKI Theliatinib: An Open Label, Dose Escalation Phase I Clinical Trial Lin Shen, Li Zhang, Hongyun Zhao, Wenfeng Fang, Jifang Gong Venue: Chinese Society of Clinical Oncology Annual Meeting Session: Esophageal Cancer Presenter: Jif
阅读更多
演示文稿, 科学出版物 | 2017-09-27

CSCO 2017: FRESCO In-Depth Analysis
In-depth Analysis of the FRESCO Study: a Randomized, Double-blind, Phase III Trial Evaluating the Efficacy and Safety of Fruquintinib in Patients with 3+ Line Advanced Colorectal Cancer Shukui QIN*, Jin LI*, Yuxian BAI, Yanhong DENG, Lei YANG, Zhen
阅读更多
演示文稿, 科学出版物 | 2017-09-27

CSCO 2017: Theliatinib Preclinical Study in Esophageal Cancer
Is EGFR a “feasible” target for advanced esophageal cancer treatment? Rongxin Ren, Shiming Fan, Linfang Wang,Min Cheng, Dongxia Shi,  Wei Zhang,Renxiang Tang, Ying Yu, Longxian Jiao, Jun Ni, Haibin Yang, Huaqing Cai,Feng Zhou, Weihan Zhang, Wei
阅读更多
公告及新闻稿, 监管通知 | 2017-08-31

Director's Share Dealing
London: Thursday, August 31, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that Mr Simon To, Executive Director and Chairman, through Dynamic Drive Limited, a person closely associated with Mr To,
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-08-29

和黄医药在中国启动高选择性PI3Kδ抑制剂HMPL-689以淋巴瘤为适应症的I期临床试验
2017年8月29日：和黄医药今日宣布在中国启动HMPL-689的I期临床试验。HMPL-689是一种新型高选择性强效小分子抑制剂，靶向B细胞受体信号通路中的关键蛋白磷酸肌醇-3激酶δ异构体（PI3Kδ）。 此
阅读更多
下载新闻稿 (PDF)
公告及新闻稿, 监管通知 | 2017-08-22

Director's Share Dealing
London: Tuesday, August 22, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that Ms Edith Shih, Non-executive Director and Company Secretary, purchased a total of 4,000 American Depositary Shares of
阅读更多
公告及新闻稿, 监管通知 | 2017-08-18

Directors' Share Dealing
London: Friday, August 18, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that:- (a) Mr Simon To, Executive Director and Chairman, through Wencheng Capital Limited (“WCL”), a person closely
阅读更多
公告及新闻稿, 监管通知 | 2017-08-15

Directors' Share Dealing
London: Tuesday, August 15, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that:- (a) Mr Simon To, Executive Director and Chairman, through Dynamic Drive Limited, a person closely associated (
阅读更多
公告及新闻稿, 监管通知 | 2017-08-10

Director’s Share Dealing
London: Thursday, August 10, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has received notifications that Ms Edith Shih, Non-executive Director and Company Secretary, purchased a total of 1,807 American Depositary Shares of th
阅读更多
公告及新闻稿, 监管通知 | 2017-08-07

Directors' Share Dealing
London: Monday, August 7, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that:- (a) Mr Simon To, Executive Director and Chairman, through Dynamic Drive Limited, a person closely associated (“P
阅读更多
公告及新闻稿, 集团 | 2017-07-31

Chi-Med Reports 2017 Interim Results and Updates Shareholders on Key Clinical Programs
London: Monday, July 31, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM), the China-based biopharmaceutical company focused on discovering and developing targeted therapies for oncology and immunological diseases for the glob
阅读更多
公告及新闻稿, 监管通知 | 2017-06-30

Total Voting Rights
London: Friday, June 30, 2017: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at June 30, 2017, the issued share capital of Chi-Med consisted of 60,737,204 ordinary shar
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-06-29

和黄医药与阿斯利康联手启动沃利替尼治疗乳头状肾细胞癌的全球III期临床试验“SAVOIR”
阿斯利康制药（“阿斯利康”） (LON/STO/NYSE: AZN) 和黄中国医药科技有限公司 （简称 “和黄医药”） （纳斯达克/伦敦证交所：HCM）   2017年6月29日： 和黄医药今日宣布将
阅读更多
下载新闻稿 (PDF)
公告及新闻稿, 监管通知 | 2017-06-29

Blocklisting Six Monthly Return
London: Thursday, June 29, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return:   1. Name of applicant: Hutchison China MediTech Limited 2. Name of sc
阅读更多
公告及新闻稿, 新闻稿, 集团 | 2017-06-29

Chi-Med to Announce 2017 Half-Year Financial Results
London: Thursday, June 29, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2017 on Monday, July 31, 2017 at 7:00 am British Summer Time (BST). An ana
阅读更多
演示文稿, 科学出版物 | 2017-06-23

Journal of Clinical Oncology: Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced PRCC
Toni K. Choueiri, Elizabeth Plimack, Hendrik-Tobias Arkenau, Eric Jonasch, Daniel Y.C. Heng, Thomas Powles, Melanie M. Frigault, Edwin A. Clark, Amir A. Handzel, Humphrey Gardner, Shethah Morgan, Laurence Albiges, and Sumanta Kumar Pal Abstract Pur
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-06-22

和黄医药在中国启动新型FGFR抑制剂HMPL 453的I/II期临床试验
2017年6月22日：和黄医药近日在中国启动HMPL-453的I/II期临床试验。HMPL-453是一种靶向成纤维细胞生长因子受体（FGFR）的新型高选择性小分子抑制剂。2017年6月19日首位受试者接受给药治疗。该
阅读更多
下载新闻稿 (PDF)
公告及新闻稿, 监管通知 | 2017-06-16

Director’s Share Dealing
London: Friday, June 16, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that:- Dynamic Drive Limited, a person closely associated (“PCA”) with Mr Simon To, Executive Director and Chairma
阅读更多
1234567891011
12
1314151617181920